Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

TesamorelinCheck methods and identity

What the current U.S. label means by excess abdominal fat

2 numbered sourcesSource years 2010, 2026

Peptides are short amino-acid chains joined by peptide bonds. Some imitate natural signals that tell the pituitary to release a hormone. Tesamorelin is a synthetic analogue of human growth hormone–releasing factor. It contains the 44-amino-acid sequence of that hormone and an added chemical group at the beginning. What does the approved indication mean when it describes a reduction in excess abdominal fat? [1]

The July 2026 U.S. prescribing information for Egrifta WR specifies adults with HIV who have lipodystrophy and excess abdominal fat. Lipodystrophy describes abnormal distribution of fat. The trials behind the labeling used imaging to assess visceral fat, which is stored around organs in the abdomen. The amount of fat under the skin, the amount of fat in a different part of the body and a person's total weight are separate measurements. The label describes the drug as having a weight-neutral effect and gives a specific approved indication rather than an indication for general weight loss. [1, 2]

The clinical trials also measured hormone and safety outcomes. By stimulating growth hormone release, tesamorelin can raise circulating insulin-like growth factor 1 (IGF-1). The label describes uncertainty about prolonged IGF-1 elevations and identifies risks including glucose intolerance, fluid retention and hypersensitivity. Some of the outcomes measured in the trials, such as blood glucose and reports of discomfort, help characterize risk separately from changes in abdominal fat. [1]

A reduced amount of visceral fat can be demonstrated with imaging during a trial. Whether it changes cardiovascular events over a much longer period requires a separate comparison. The current label explicitly states that long-term cardiovascular safety has not been established. It also treats Egrifta WR and Egrifta SV as distinct formulations with separate prescribing information. Shared active ingredients do not make all details of formulation and evidence interchangeable. [1]

The current U.S. label describes a specified product, purpose and patient group. Older randomized evidence supports the visceral-fat outcome in the studied population. It does not show that a different product bearing the same ingredient name has the same characteristics or that the same effect applies to every reason for gaining abdominal fat. [1, 2]

Sources

Original works cited in this article. Links open the external record in a new tab.

Shop Tesamorelin

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Also available as Markdown or JSON.